Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs is organized by Rockpointe Corporation.

Release Date: Nov 16, 2022
Expiration Date: Nov 16, 2023

Description:
Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver. 

Educational Objectives:
At the conclusion of this education, participants should be able to:
• Discuss the etiology of anemia in chronic kidney disease
• Summarize how anemia affects functioning, quality of life, and health outcomes, for patients with cardiovascular disease and chronic kidney disease
• Assess the benefits and limitations of available modalities for treating anemia in chronic kidney disease
• Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease